期刊文献+

^(90)Y标记单克隆抗体用于放免治疗的研究Ⅰ.四种^(90)Y标记物的24小 被引量:4

LABELING MoAb WITH  ̄(90)Y EOR RADIOIMMUNOTHERAPY Ⅰ.BIODISTRIBUTIONS FOR FOUR  ̄(90)Y-LABELED COMPOUNDS AT 24 HOURS AFTER ADMINISTRATION
暂未订购
导出
摘要 研究了(90) ̄YCl_3,(90) ̄Y-DTPA,(90) ̄Y-DOTA和(90) ̄Y-DTPA-IgG的制备方法及其在小鼠体内的生物分布。(90) ̄YCl_3的主要积聚器官是骨,在其它组织代谢较快。(90) ̄Y-DTPA和(90) ̄Y-DTPA-IgG在体内有较严重的(90) ̄Y脱落;(90) ̄Y-DOTA有效地改善了(90) ̄Y在骨中的积聚,表明大环DOTA类衍生物是(90) ̄Y标记单克隆抗体良好的配体。 ?90)YCl_3, ̄(90)Y-DTPA  ̄(90)Y-DOTA and  ̄(90)Y-DTPA-IgG were prepared and their biodistributions are in-vestigated. Unchelated  ̄(90)Yachieves a high uptake in bone and has a rapid clearance in other tissues;There is a serious loss of  ̄(90)Y in vivo from  ̄(90)Y-DTPA and  ̄(90)Y-DTPA- IgG; ̄(90)Y-DOTA obviously re-duces the accumulation of ̄(90)Yin bone. The result shows that DOTA is a prospective bifunctional chelat-ing agent for labeling MoAb with ̄(90)Y.
出处 《同位素》 CAS 北大核心 1994年第2期98-102,共5页 Journal of Isotopes
关键词 标记 单克隆抗体 生物分布 镱90 radioimmunotherapy labeling monoclonal antibody biodistribution
  • 相关文献

同被引文献40

  • 1张锦明,林琼芳.^90Y标记单克隆抗体3H11[J].中华核医学杂志,1993,13(3):173-175. 被引量:3
  • 2贾海威,聂青,张伟京,宋海峰,刘秀文,朱宝珍.美罗华单抗的^(90)Y标记的实验研究[J].第二军医大学学报,2005,26(12):1412-1414. 被引量:1
  • 3钟高仁,朱建华,朱桐.单克隆抗体Lym—1的^(90)Y预标记法研究[J].核技术,1996,19(7):440-444. 被引量:1
  • 4吕发度,董荣春,刘振华,陈永裕,刘植珊,李光业.人体骨肉瘤细胞系的建立及其生物学特性观察[J].第二军医大学学报,1990,11(3):257-260. 被引量:7
  • 5陈永裕,刘振华,徐登仁,沈茜,陈舰.裸鼠人成骨肉瘤骨模型的建立[J].第二军医大学学报,1990,11(6):495-497. 被引量:6
  • 6Wiseman GA,White CA,Sparks RB,et al.Biodistribution and dosimetry results from a phase Ⅲ prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade,follicular,or transformed B-cell non-Hodgkin's lymphoma[J].Oncol Hematol,2001,39(1-2):181-94.
  • 7Shan D,Ledbetter JA,Press OW.Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells[J].Cancer Immunol Immunother,2000,48(12):673-683.
  • 8Wagner HN Jr,Wiseman GA,Marcus CS,et al.Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody[J].J Nucl Med,2002,43(2):267-272.
  • 9Wessels BW,Rogus RD.Radionuclide selection and model absorbed dose calculation for radiolabeled tumor associated antibodies[J].Med Phys,1984,11(5):638-645.
  • 10Stimmel JB,Stockstill ME,Kull FC Jr.90Y chelation properties of tetraazatetraacetic acid macrocycles,diethylenetriaminepentaacetic acid analogues,and a novel terpyridine acyclic chelator[J].Bioconjug Chem,1995,6(2):219-225.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部